Literature DB >> 16641257

A tryptophan-rich motif in the carboxyl terminus of the small envelope protein of hepatitis B virus is central to the assembly of hepatitis delta virus particles.

Isabelle Komla-Soukha1, Camille Sureau.   

Abstract

The small hepatitis B virus surface antigen (S-HBsAg) is capable of driving the assembly and secretion of hepatitis delta virus (HDV) particles by interacting with the HDV ribonucleoprotein (RNP). Previously, a specific domain of the S-HBsAg protein carboxyl terminus, including a tryptophan residue at position 196 (W196), was proven essential for HDV maturation (S. Jenna and C. Sureau, J. Virol. 73: 3351-3358, 1999). Mutation of W196 to phenylalanine (W196F) was permissive for HBV subviral particle (SVP) secretion but deleterious to HDV virion assembly. Here, the W196F S-HBsAg deficiency was assigned to a loss of its ability for interaction with the large HDV antigen (L-HDAg), a major component of the RNP. Because the overall S-HBsAg carboxyl terminus is particularly rich in tryptophan, an amino acid frequently involved in protein-protein interactions, site-directed mutagenesis was conducted to investigate the function of the S-HBsAg Trp-rich domain in HDV assembly. Single substitutions of tryptophan between positions 163 and 201 with alanine or phenylalanine were tolerated for SVP secretion, but those affecting W196, W199, and W201 were detrimental for HDV assembly. This was proven to result from a reduced capacity of the mutants for interaction with L-HDAg. In addition, a W196S S-HBsAg mutant, which has been described in HBV strains that arose in a few cases of lamivudine-treated HBV-infected patients, was deficient for HDV assembly as a consequence of its impaired capacity for interacting with L-HDAg. Interestingly, the fact that even the most conservative substitution of phenylalanine for tryptophan at positions 196, 199, or 201 was sufficient to ablate interaction of S-HBsAg with L-HDAg suggests that W196, W199, and W201 are located at a binding interface that is central to HDV maturation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16641257      PMCID: PMC1472050          DOI: 10.1128/JVI.80.10.4648-4655.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

Review 1.  The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains.

Authors:  B K Kay; M P Williamson; M Sudol
Journal:  FASEB J       Date:  2000-02       Impact factor: 5.191

2.  Protein-protein interactions: structurally conserved residues distinguish between binding sites and exposed protein surfaces.

Authors:  Buyong Ma; Tal Elkayam; Haim Wolfson; Ruth Nussinov
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-01       Impact factor: 11.205

3.  A hepatitis B surface antigen mutant that lacks the antigenic loop region can self-assemble and interact with the large hepatitis delta antigen.

Authors:  Brendan O'Malley; David Lazinski
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

4.  Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy.

Authors:  Joseph Torresi; Linda Earnest-Silveira; Georgia Deliyannis; Kristy Edgtton; Hui Zhuang; Stephen A Locarnini; Janet Fyfe; Tina Sozzi; David C Jackson
Journal:  Virology       Date:  2002-02-15       Impact factor: 3.616

5.  Role of the antigenic loop of the hepatitis B virus envelope proteins in infectivity of hepatitis delta virus.

Authors:  Georges Abou Jaoudé; Camille Sureau
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

6.  Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene.

Authors:  Joseph Torresi; Linda Earnest-Silveira; Gilda Civitico; Tomos E Walters; Sharon R Lewin; Janet Fyfe; Stephen A Locarnini; Michael Manns; Christian Trautwein; Thomas C Bock
Journal:  Virology       Date:  2002-07-20       Impact factor: 3.616

7.  Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy.

Authors:  Hubert G M Niesters; Robert A DE Man; Suzan D Pas; Edwin Fries; Albert D M E Osterhaus
Journal:  J Med Microbiol       Date:  2002-08       Impact factor: 2.472

8.  Role of N glycosylation of hepatitis B virus envelope proteins in morphogenesis and infectivity of hepatitis delta virus.

Authors:  Camille Sureau; Chantal Fournier-Wirth; Patrick Maurel
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

9.  Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades.

Authors:  Nadjia Radjef; Emmanuel Gordien; Valeria Ivaniushina; Elyanne Gault; Patricia Anaïs; Tudor Drugan; Jean-Claude Trinchet; Dominique Roulot; Mathieu Tamby; Michel C Milinkovitch; Paul Dény
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

Review 10.  The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus.

Authors:  Joseph Torresi
Journal:  J Clin Virol       Date:  2002-08       Impact factor: 3.168

View more
  27 in total

1.  Large hepatitis delta antigen is a novel clathrin adaptor-like protein.

Authors:  Cheng Huang; Shin C Chang; I-Chen Yu; Yeou-Guang Tsay; Ming-Fu Chang
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

2.  Two potentially important elements of the hepatitis B virus large envelope protein are dispensable for the infectivity of hepatitis delta virus.

Authors:  Severin Gudima; Anja Meier; Roland Dunbrack; John Taylor; Volker Bruss
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

3.  Clathrin-mediated post-Golgi membrane trafficking in the morphogenesis of hepatitis delta virus.

Authors:  Cheng Huang; Shin C Chang; Hui-Chin Yang; Chung-Liang Chien; Ming-Fu Chang
Journal:  J Virol       Date:  2009-09-30       Impact factor: 5.103

4.  Molecular interactions between hepatitis B virus and delta virus.

Authors:  Elham Shirvani-Dastgerdi; Frank Tacke
Journal:  World J Virol       Date:  2015-05-12

5.  Infectivity determinants of the hepatitis B virus pre-S domain are confined to the N-terminal 75 amino acid residues.

Authors:  Matthieu Blanchet; Camille Sureau
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

6.  Hepatitis Delta Virus Alters the Autophagy Process To Promote Its Genome Replication.

Authors:  Marwa Khabir; Asma Zahra Aliche; Camille Sureau; Matthieu Blanchet; Patrick Labonté
Journal:  J Virol       Date:  2020-01-31       Impact factor: 5.103

Review 7.  The alternative translational profile that underlies the immune-evasive state of persistence in Chlamydiaceae exploits differential tryptophan contents of the protein repertoire.

Authors:  Chien-Chi Lo; Gary Xie; Carol A Bonner; Roy A Jensen
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

8.  A Sporozoite- and Liver Stage-expressed Tryptophan-rich Protein Plays an Auxiliary Role in Plasmodium Liver Stage Development and Is a Potential Vaccine Candidate.

Authors:  Dabbu Kumar Jaijyan; Himanshu Singh; Agam Prasad Singh
Journal:  J Biol Chem       Date:  2015-05-10       Impact factor: 5.157

9.  Domains of the Hepatitis B Virus Small Surface Protein S Mediating Oligomerization.

Authors:  Sascha Suffner; Nadine Gerstenberg; Maria Patra; Paula Ruibal; Ahmed Orabi; Michael Schindler; Volker Bruss
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

10.  Hepatitis B surface antigen levels and sequences of natural hepatitis B virus variants influence the assembly and secretion of hepatitis d virus.

Authors:  Hsuan Hui Shih; King-Song Jeng; Wan-Jr Syu; Yi-Hsiang Huang; Chien-Wei Su; Wei-Li Peng; I-Jane Sheen; Jaw-Ching Wu
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.